Early fulminant leukaemia post autologous bone marrow transplantation in non-Hodgkin's lymphoma patients.
Although autologous bone marrow transplantation (ABMT) is a curative option for about 50% of the patients with progressive or relapsing lymphomas, considerable concern has been raised recently over the emerging rates of secondary malignancies following ABMT. A 15% cumulative incidence of myelodysplasia 5 years after BMT is of major concern. We hereby describe a unique form of leukaemia occurring 4-6 weeks post ABMT for non-Hodgkin's lymphoma patients. The possible etiology for this phenomenon as well as its relation to the classical MDS post ABMT is discussed.
Toren
A
A
Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel.
Rechavi
G
G
Nagler
A
A
D000208:Acute Disease; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000209:etiology*; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014182:Transplantation, Autologous; D017211:Treatment Failure